Sign in
New Tool for Predicting the 3-Year Risk of Vision-Threatening Diabetic Retinopathy in Patients With Type 2 Diabetes Mellitus
Bobeck S Modjtahedi, MD
Annual Meeting Talks
2022
Intravitreal Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy: One-Year Primary Outcomes From the Randomized RECOVERY Trial
Charles C Wykoff, MD, PhD, FASRS
2019
A Randomized Trial of Intravitreous Anti-VEGF for Prevention of Vision Threatening Complications of Diabetic Retinopathy (Protocol W)
Raj K. Maturi, MD
Updates from the Field
2021
Category: Diabetic Retinopathy